Cephalon Inc

Cephalon — Merger or Acquisition (February 2010)

10 slides from Cephalon's merger presentation, Feb 4, 2010

  1. Slide 1: Mepha Acquisition Conference Call February 1, 2010

    Mepha Acquisition Conference Call February 1, 2010

  2. Slide 2: Cephalon Perspective: How Does Mepha Add To Cephalon?

    Cephalon Perspective How Does Mepha Add To Cephalon? Increased global reach: We can leverage our current and future products through Mepha $400 million of incremental sales: Mepha doubles the size of our international business with a sound, diverse product portfolio Increased balance: We now serve a

  3. Slide 3: Mepha Company Profile

    MEPHA Company Profile A fully integrated profitable branded generics & specialty pharmaceutical company structured around: Switzerland pharmaceutical operations International pharmaceutical operations Manufacturing & supply chain Development (pilot unit, formulation improvements) Stand-alone company

  4. Slide 4: Estimated 2009 net sales of 408MM CHF

    MEPHA Company Profile 408MM CHF estimated net sales in 2009 (approx. $400 million) Sales CAGR of 13% over the last five years Excellent complement to our existing business

  5. Slide 5: Existing Product Portfolio

    MEPHA Company Profile Existing Product Portfolio About 120 products: Improved Branded Generics (i.e. modified release) Branded generics Generics Limited Rx-OTC product range in selected countries 20 top selling products generate over 60% of 2009 sales Patented formulation technologies: Patches Gels

  6. Slide 6: Mepha Company Profile: Innovative Dosage Forms For Better Application

    Mepha Company Profile Innovative Dosage Forms For Better Application Depocaps™ - capsules filled with a number of slow-release pellets designed for a pH-independent sustained release Gastrocaps™ - enteric coated pellets protects active compounds from acidic gastric juice and ensures release in the s

  7. Slide 7: Existing Product Portfolio

    MEPHA Company Profile Existing Product Portfolio Mephaquin™ - Prophylaxis of malaria Mepharis™ - Schizophrenia Mesporin™ - Moderate to severe bacterial infections Neurorubine™ - Neuralgic pain; nerve damage due to diabetes or alcoholism Olfen™ - Acute painful inflammatory conditions Pectoral™ - Coug

  8. Slide 8: Planned Product Launches

    MEPHA Company Profile Planned Product Launches Targeting future high selling off-patent products New products in-licensed or internally-developed Close to 150 identified commercial launches planned between 2010 and 2014 (50 chemical entities) Planned product launches 34 33 34 23 28 0 10 20 30 40 201

  9. Slide 9: Cephalon With The Addition Of Mepha

    Cephalon With The Addition Of Mepha Global Bio-pharmaceutical company Sales presence in 100 countries 3,800 employees 30 percent of sales outside United States Diverse product portfolio Increasingly stable, and profitable business Deep pipeline: oncology, pain, inflammatory diseases, branded generic

  10. Slide 10: Thank you!

    {4 Cephalon Thank you! February 1, 2010

Cephalon — Merger or Acquisition (February 2010) on 6ix